MAPS
In MAPS, adding the anti-VEGF antibody bevacizumab to chemotherapy lengthened survival by about three months, the first improvement after pemetrexed.
OS 18.8 vs 16.1 months (HR 0.77). Bevacizumab is NCCN-listed for mesothelioma but never received an FDA indication; use varies. Established angiogenesis as a valid target in the disease.
Setting
Unresectable pleural mesothelioma, first line: cisplatin-pemetrexed ± bevacizumab
Phase
Phase 3
Sponsor
IFCT (France)
Registry
Headline result
OS 18.8 vs 16.1 months, HR 0.77.
Reported
2016
Enrolled
448
Replication
Not replicated by a second phase 3; nintedanib (LUME-Meso) failed to reproduce the anti-angiogenic benefit.
In plain words
What these results mean for people, not percentages
Overall survivalprimarysurvival endpoint
- Median 18.8 vs 16.1 months with Chemotherapy + bevacizumab compared with Chemotherapy; about 2.7 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 23 percent lower chance of the event at any given time (hazard ratio 0.77, likely range 0.62 to 0.95).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Unresectable pleural mesothelioma, first line: cisplatin-pemetrexed ± bevacizumab. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
448 participants enrolled.
Overall survivalprimary
HR 0.77 (0.62–0.95) · p = 0.0167
Chemotherapy + bevacizumab
18.8 mo
Chemotherapy
16.1 mo
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | Chemotherapy + bevacizumab | 223 | 18.8 months | 0.77 (0.62–0.95) | 0.0167 | link |
| Chemotherapy | 225 | 16.1 months |
Replication
Not replicated by a second phase 3; nintedanib (LUME-Meso) failed to reproduce the anti-angiogenic benefit.